iRhythm Technologies - IRTC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $116.10
  • Forecasted Upside: 88.38%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$61.63
▼ -1.08 (-1.72%)

This chart shows the closing price for IRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

Analyst Price Target is $116.10
▲ +88.38% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $116.10, with a high forecast of $145.00 and a low forecast of $78.00. The average price target represents a 88.38% upside from the last price of $61.63.

This chart shows the closing price for IRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in iRhythm Technologies. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/14/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/12/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/4/2024The Goldman Sachs GroupInitiated CoverageNeutral$78.00
9/25/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$122.00 ➝ $137.00
8/22/2024CitigroupLower TargetBuy ➝ Buy$135.00 ➝ $110.00
8/2/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$133.00 ➝ $100.00
8/2/2024OppenheimerLower TargetOutperform ➝ Outperform$165.00 ➝ $145.00
8/2/2024Robert W. BairdLower TargetOutperform ➝ Outperform$120.00 ➝ $110.00
8/2/2024Truist FinancialReiterated RatingBuy ➝ Buy$134.00 ➝ $117.00
8/2/2024Needham & Company LLCLower TargetBuy ➝ Buy$138.00 ➝ $119.00
7/16/2024Truist FinancialLower TargetBuy ➝ Buy$145.00 ➝ $134.00
7/15/2024Morgan StanleyLower TargetOverweight ➝ Overweight$135.00 ➝ $130.00
6/20/2024Wolfe ResearchUpgradePeer Perform ➝ Outperform$115.00
5/3/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$133.00 ➝ $122.00
5/3/2024Needham & Company LLCBoost TargetBuy ➝ Buy$137.00 ➝ $138.00
2/23/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$142.00 ➝ $133.00
2/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$121.00 ➝ $133.00
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$136.00 ➝ $137.00
1/8/2024Needham & Company LLCBoost TargetBuy ➝ Buy$108.00 ➝ $136.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$115.00 ➝ $133.00
12/12/2023Truist FinancialBoost TargetBuy ➝ Buy$100.00 ➝ $115.00
12/11/2023CitigroupUpgradeNeutral ➝ Buy$110.00
11/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$140.00 ➝ $108.00
10/11/2023Morgan StanleyLower TargetOverweight ➝ Overweight$149.00 ➝ $135.00
10/2/2023CitigroupLower Target$115.00 ➝ $100.00
8/28/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$136.00 ➝ $116.00
8/7/2023Truist FinancialLower TargetBuy ➝ Buy$155.00 ➝ $138.00
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$149.00
8/4/2023OppenheimerBoost Target$125.00 ➝ $165.00
8/4/2023Needham & Company LLCLower TargetBuy ➝ Buy$151.00 ➝ $130.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$130.00
6/8/2023BTIG ResearchLower Target$165.00 ➝ $140.00
5/5/2023VNET GroupReiterated RatingMaintains
5/5/2023Needham & Company LLCBoost Target$133.00 ➝ $151.00
5/5/2023CitigroupBoost Target$130.00 ➝ $135.00
4/17/2023Truist FinancialBoost TargetBuy$137.00 ➝ $154.00
4/17/2023BTIG ResearchBoost TargetBuy$168.00 ➝ $170.00
4/3/2023CitigroupBoost TargetNeutral$110.00 ➝ $130.00
2/24/2023Needham & Company LLCLower TargetBuy$140.00 ➝ $133.00
2/24/2023Morgan StanleyBoost TargetOverweight$128.00 ➝ $130.00
2/24/2023Canaccord Genuity GroupBoost TargetBuy$135.00 ➝ $143.00
2/7/2023Wells Fargo & CompanyInitiated CoverageOverweight$150.00
1/6/2023Morgan StanleyLower TargetOverweight$165.00 ➝ $128.00
12/20/2022Truist FinancialLower TargetBuy$167.00 ➝ $153.00
12/12/2022CitigroupLower TargetNeutral$144.00 ➝ $110.00
11/7/2022Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
11/2/2022OppenheimerLower Target$175.00 ➝ $166.00
11/2/2022Needham & Company LLCLower TargetBuy$185.00 ➝ $140.00
11/2/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$198.00 ➝ $155.00
11/2/2022CitigroupLower TargetNeutral$147.00 ➝ $144.00
10/20/2022BTIG ResearchLower Target$175.00
10/17/2022Truist FinancialLower TargetBuy$185.00 ➝ $167.00
10/11/2022Morgan StanleyLower TargetOverweight$172.00 ➝ $165.00
10/5/2022CitigroupLower Target$157.00 ➝ $147.00
9/22/2022Morgan StanleyLower TargetOverweight$190.00 ➝ $172.00
9/22/2022JPMorgan Chase & Co.Boost TargetOverweight$185.00 ➝ $190.00
9/2/2022Canaccord Genuity GroupBoost TargetBuy$185.00 ➝ $198.00
8/9/2022CitigroupBoost Target$157.00
8/5/2022BTIG ResearchBoost TargetBuy$155.00 ➝ $178.00
6/24/2022BTIG ResearchLower TargetBuy$180.00 ➝ $155.00
6/22/2022JPMorgan Chase & Co.Reiterated RatingOverweight$183.00 ➝ $135.00
6/16/2022Truist FinancialLower TargetBuy$200.00 ➝ $165.00
6/9/2022CitigroupDowngradeBuy ➝ Neutral$180.00 ➝ $155.00
5/6/2022CitigroupBoost Target$175.00 ➝ $180.00
4/5/2022Wolfe ResearchInitiated CoverageUnderperform$105.00
4/4/2022JPMorgan Chase & Co.Boost TargetOverweight$156.00 ➝ $192.00
2/24/2022Morgan StanleyLower TargetOverweight$167.00 ➝ $151.00
2/24/2022Needham & Company LLCUpgradeHold ➝ Buy$135.00
1/27/2022JPMorgan Chase & Co.Boost TargetOverweight$116.00 ➝ $156.00
1/18/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$129.00 ➝ $167.00
1/14/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$125.00 ➝ $160.00
1/14/2022CitigroupBoost TargetBuy$120.00 ➝ $165.00
1/13/2022Truist FinancialBoost Target$130.00 ➝ $185.00
1/12/2022Robert W. BairdBoost Target$110.00 ➝ $137.00
1/12/2022BTIG ResearchUpgradeNeutral ➝ Buy$170.00
1/11/2022OppenheimerUpgradeMarket Perform ➝ Outperform$150.00
1/7/2022Morgan StanleyBoost TargetEqual Weight$114.00 ➝ $129.00
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $116.00
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00
11/8/2021Morgan StanleyBoost TargetEqual Weight$77.00 ➝ $114.00
11/5/2021CitigroupBoost TargetNeutral$60.00 ➝ $120.00
10/14/2021JPMorgan Chase & Co.Boost TargetNeutral$55.00 ➝ $70.00
10/1/2021CitigroupBoost TargetNeutral$55.00 ➝ $60.00
8/6/2021CitigroupLower TargetNeutral$74.00 ➝ $55.00
6/3/2021Morgan StanleyLower TargetEqual Weight$94.00 ➝ $85.00
6/2/2021Needham & Company LLCReiterated RatingHold
6/2/2021CitigroupDowngradeBuy ➝ Neutral
4/20/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$288.00 ➝ $94.00
4/19/2021BTIG ResearchReiterated RatingBuy ➝ Neutral
4/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$288.00 ➝ $94.00
4/13/2021Truist FinancialLower Target$220.00 ➝ $115.00
4/13/2021BTIG ResearchDowngradeBuy ➝ Neutral
4/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$215.00 ➝ $95.00
4/12/2021Robert W. BairdLower TargetNeutral$170.00 ➝ $80.00
3/4/2021Colliers SecuritiesReiterated RatingBuy ➝ Neutral
3/1/2021CitigroupLower TargetBuy$252.00 ➝ $195.00
2/28/2021Robert W. BairdReiterated RatingHold
2/26/2021Colliers SecuritiesDowngradeBuy ➝ Neutral
2/4/2021BTIG ResearchLower TargetBuy$283.00 ➝ $210.00
2/1/2021Truist FinancialLower Target$265.00 ➝ $220.00
1/29/2021Needham & Company LLCReiterated RatingHold
1/25/2021Morgan StanleyBoost TargetOverweight$227.00 ➝ $288.00
1/21/2021BTIG ResearchBoost TargetBuy$235.00 ➝ $283.00
12/15/2020Morgan StanleyLower TargetOverweight$230.00 ➝ $227.00
12/10/2020William BlairReiterated RatingBuy
12/3/2020Truist FinancialLower Target$265.00 ➝ $240.00
12/3/2020Smith Barney CitigroupLower Target$275.00 ➝ $238.00
12/3/2020Robert W. BairdLower TargetNeutral$220.00 ➝ $170.00
12/2/2020Morgan StanleyLower TargetOverweight$270.00 ➝ $230.00
11/17/2020OppenheimerDowngradeOutperform ➝ Market Perform
11/17/2020Needham & Company LLCReiterated RatingHold
11/6/2020Truist FinancialBoost Target$200.00 ➝ $265.00
11/6/2020Morgan StanleyBoost TargetOverweight$259.00 ➝ $270.00
11/6/2020OppenheimerReiterated RatingBuy$200.00 ➝ $250.00
10/12/2020BTIG ResearchBoost Target$130.00 ➝ $160.00
9/11/2020Needham & Company LLCInitiated CoverageHold
9/1/2020Robert W. BairdInitiated CoverageNeutral$220.00
8/25/2020CitigroupBoost TargetBuy$215.00 ➝ $250.00
8/7/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$200.00
8/5/2020CitigroupBoost TargetBuy$147.00 ➝ $200.00
8/5/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$125.00 ➝ $140.00
5/8/2020Morgan StanleyBoost TargetOverweight$114.00 ➝ $142.00
5/8/2020SunTrust BanksBoost TargetBuy$102.00 ➝ $130.00
5/8/2020BTIG ResearchReiterated RatingBuy$130.00
5/8/2020OppenheimerReiterated RatingHold
3/27/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $114.00
3/27/2020CitigroupLower TargetBuy$120.00 ➝ $112.00
3/4/2020CitigroupInitiated CoverageBuy$120.00
2/5/2020BTIG ResearchInitiated CoverageBuy$90.00
1/9/2020William BlairInitiated CoverageOutperform
1/7/2020SunTrust BanksInitiated CoverageBuy$102.00
12/17/2019Morgan StanleyBoost TargetOverweight$101.00 ➝ $110.00
10/22/2019OppenheimerInitiated CoverageMarket Perform
(Data available from 10/7/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 69 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
3/11/2024
  • 10 very positive mentions
  • 44 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/10/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/10/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/9/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2024
  • 16 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/8/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/7/2024
  • 11 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/7/2024

Current Sentiment

  • 11 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $61.63
Low: $61.37
High: $62.91

50 Day Range

MA: $71.54
Low: $62.71
High: $89.10

52 Week Range

Now: $61.63
Low: $60.88
High: $124.11

Volume

136,279 shs

Average Volume

441,508 shs

Market Capitalization

$1.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: Canaccord Genuity Group Inc., Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and Wolfe Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

10 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $116.10, suggesting a possible upside of 88.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting IRTC will reach $145.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $78.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

Other companies that are similar to iRhythm Technologies include Nevro, Haemonetics, Penumbra, Bausch + Lomb and Glaukos. Learn More about companies similar to iRhythm Technologies.

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is (415) 632-5700 and its investor relations email address is [email protected]. The official website for iRhythm Technologies is www.irhythmtech.com. Learn More about contacing iRhythm Technologies investor relations.